Coeptis Therapeutics Holdings
Wexford, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into Coeptis Therapeutics Holdings
Sign up to see every warm intro you have to Coeptis Therapeutics Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Coeptis Therapeutics Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DY
Daniel YeraceExecutive
BC
Brian CogleyExecutive
DM
David MehalickNamed on SEC filing
Board
GS
Gene SalkindBoard director
CC
Christopher CochranBoard director
CC
Christopher CaliseBoard director
TM
Tara Maria DeSilvaBoard director
PD
Philippe DeschampsBoard director
Investors · 1
Also in the syndicate · 1
CJC Investment Trustlead
Reported raises · per SEC filings
Form D private placements$10.3M disclosed across 3 rounds · 2023–2025
▶$4MraisedAug 2025 · 9 investors · PharmaceuticalsRule 506(b)
▶$4MraisedAug 2025 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher CochranDirector
- David MehalickExecutive Officer, Director
- Christopher CaliseDirector
- Tara Maria DeSilvaDirector
- Daniel YeraceDirector
- Brian CogleyExecutive Officer
- Gene SalkindDirector
- Philippe DeschampsDirector
- Offering amount
- $5M
- Amount sold
- $4M
- Minimum investment
- $100K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$4.3MraisedJun 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedJun 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher CochranDirector
- Gene SalkindDirector
- David MehalickExecutive Officer, Director
- Colleen DelaneyExecutive Officer
- Christine SheehyExecutive Officer
- Tara Maria DeSilvaDirector
- Philippe DeschampsDirector
- Brian CogleyExecutive Officer
- Daniel YeraceExecutive Officer, Director
- Christopher CaliseDirector
- Offering amount
- $10M
- Amount sold
- $4.3M
- Minimum investment
- $100K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$2MraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David MehalickExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Coeptis Therapeutics Holdings raised?
- Coeptis Therapeutics Holdings has disclosed $10.3M raised across 3 rounds.
- Where is Coeptis Therapeutics Holdings headquartered?
- Coeptis Therapeutics Holdings is headquartered in Wexford, US.